Jason B. Fleming

Jason B. Fleming

Auto-generated profile, based on publicly available information

Jason B. Fleming

Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2017 in Science
Verified
Journal Article
Closed access
PDF file
LGLeore T. Geller
Leore T. Geller
MBMichal Barzily-Rokni
Michal Barzily-Rokni
TDTal Danino
Tal Danino
OJOliver H. Jonas
Oliver H. Jonas
NSNoam Shental
Noam Shental
RSRavid Straussman
Ravid Straussman
Growing evidence suggests that microbes can influence the efficacy of cancer therapies. By studying colon cancer models, we found that bacteria can metabolize the chemotherapeutic drug gemcitabine (2′,2′-difluorodeoxycytidine) into its inactive form, 2′,2′-difluorodeoxyuridine. Metabolism was dependent on the expression of a long isoform of the bacterial enzyme cytidine deaminase (CDDL), seen primarily in Gammaproteobacteria. In a colon cancer mouse model, gemcitabine resistance was induced by intratumor Gammaproteobacteria, dependent on bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin. Gemcitabine is commonly used to treat pancreatic ductal adenocarcinoma (PDAC), and we hypothesized that intratumor bacteria might contribute to drug resistance of these tumors. Consistent with this possibility, we found that of the 113 human PDACs that were tested, 86 (76%) were positive for bacteria, mainly Gammaproteobacteria.

10 March 2014 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
EKEugene J. Koay
Eugene J. Koay
MTMark J. Truty
Mark J. Truty
VCVittorio Cristini
Vittorio Cristini
RTRyan M. Thomas
Ryan M. Thomas
RCRong Chen
Rong Chen
JFJason B. Fleming
Jason B. Fleming
Background. The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence delivery of and response to gemcitabine-based therapy. Methods. We developed a method to measure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumors. Additionally, we evaluated gemcitabine infusion during PDAC resection in 12 patients, measuring gemcitabine incorporation into tumor DNA and correlating its uptake with human equilibrative nucleoside transporter (hENT1) levels, stromal reaction, and CT-derived mass transport properties. We also studied associations between CT-derived transport properties and clinical outcomes in patients who received preoperative gemcitabine-based chemoradiotherapy for resectable PDAC. Results. Transport modeling of 176 CT scans illustrated striking differences in transport properties between normal pancreas and tumor, with a wide array of enhancement profiles. Reflecting the interpatient differences in contrast enhancement, resected tumors exhibited dramatic differences in gemcitabine DNA incorporation, despite similar intravascular pharmacokinetics. Gemcitabine incorporation into tumor DNA was inversely related to CT-derived transport parameters and PDAC stromal score, after accounting for hENT1 levels. Moreover, stromal score directly correlated with CT-derived parameters. Among 110 patients who received preoperative gemcitabine-based chemoradiotherapy, CT-derived parameters correlated with pathological response and survival. Conclusion. Gemcitabine incorporation into tumor DNA is highly variable and correlates with multiscale transport properties that can be derived from routine CT scans. Furthermore, pretherapy CT-derived properties correlate with clinically relevant endpoints. Trial registration. Clinicaltrials.gov NCT01276613. Funding. Lustgarten Foundation (989161), Department of Defense (W81XWH-09-1-0212), NIH (U54CA151668, KCA088084).

22 August 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
MYMeifang Yu
Meifang Yu
NNNicholas Nguyen
Nicholas Nguyen
YHYanqing Huang
Yanqing Huang
Daniel LinDaniel Lin
Daniel Lin
TFTara N. Fujimoto
Tara N. Fujimoto
Cullen M. TaniguchiCullen M. Taniguchi
Cullen M. Taniguchi
Pancreatic ductal adenocarcinoma (PDAC) requires mitochondrial oxidative phosphorylation (OXPHOS) to fuel its growth; however, broadly inhibiting this pathway might also disrupt essential mitochondrial functions in normal tissues. PDAC cells exhibit abnormally fragmented mitochondria that are essential to the oncogenicity of PDAC, but it was unclear if this mitochondrial feature was a valid therapeutic target. Here, we present evidence that normalizing the fragmented mitochondria of pancreatic cancer via the process of mitochondrial fusion reduces OXPHOS, which correlates with suppressed tumor growth and improved survival in preclinical models. Mitochondrial fusion was achieved by genetic or pharmacologic inhibition of dynamin-related protein-1 (Drp1) or through overexpression of mitofusin-2 (Mfn2). Notably, we found that oral leflunomide, an FDA-approved arthritis drug, promoted a 2-fold increase in Mfn2 expression in tumors and was repurposed as a chemotherapeutic agent, improving the median survival of mice with spontaneous tumors by 50% compared with vehicle. We found that the chief tumor-suppressive mechanism of mitochondrial fusion was enhanced mitophagy, which proportionally reduced mitochondrial mass and ATP production. These data suggest that mitochondrial fusion is a specific and druggable regulator of pancreatic cancer growth that could be rapidly translated to the clinic.

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JDJenying Deng
Jenying Deng
YKYaan Kang
Yaan Kang
CCChien-Chia Cheng
Chien-Chia Cheng
XLXinqun Li
Xinqun Li
BDBingbing Dai
Bingbing Dai
JFJason B. Fleming
Jason B. Fleming
Pancreatic ductal adenocarcinoma (PDAC) tumors are characterized by a desmoplastic reaction resulting in dense deposition of collagen that is known to promote cancer progression. A central mediator of protumorigenic collagen signaling is the receptor tyrosine kinase discoid domain receptor 1 (DDR1). DDR1 is a critical driver of a mesenchymal and invasive cancer cell PDAC phenotype. Previous studies have demonstrated that genetic or pharmacologic inhibition of DDR1 reduces PDAC tumorigenesis and metastasis. Here, we investigated whether DDR1 signaling has cancer cell nonautonomous effects that promote PDAC progression and metastasis. We demonstrate that collagen-induced DDR1 activation in cancer cells is a major stimulus for CXCL5 production, resulting in the recruitment of tumor-associated neutrophils (TANs), the formation of neutrophil extracellular traps (NETs), and subsequent cancer cell invasion and metastasis. Moreover, we have identified that collagen-induced CXCL5 production was mediated by a DDR1/PKC θ /SYK/NF- κ B signaling cascade. Together, these results highlight the critical contribution of the collagen I–DDR1 interaction in the formation of an immune microenvironment that promotes PDAC metastasis.

29 October 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
CRChristina L. Roland
Christina L. Roland
AYAnthony D. Yang
Anthony D. Yang
MKMatthew H. G. Katz
Matthew H. G. Katz
DCDeyali Chatterjee
Deyali Chatterjee
HWHuamin Wang
Huamin Wang
JFJason B. Fleming
Jason B. Fleming

9 May 2013 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
CLChristine S. Landry
Christine S. Landry
HLHeather Y. Lin
Heather Y. Lin
APAlexandria Phan
Alexandria Phan
CCChusilp Charnsangavej
Chusilp Charnsangavej
EAEddie K. Abdalla
Eddie K. Abdalla
JFJason B. Fleming
Jason B. Fleming